Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 in combination with chemotherapy and adebrelimab for pancreatic cancer
NCT07296341Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in pancreatic adenocarcinoma (PDAC), sponsored by Hengrui Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07296341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07296341.